AR-V7 Mutation Detection Kit

Companion Diagnostics for Precision Medicine

About MEDx
Technology Centers
Pharma Solutions
CDx/IVD Products

Assays by Platforms

IHC-Based Assays

PCR-Based Assays

NGS-Based Assays

More Assays

Customized Assays

IHC-Based Assays

PCR-Based Assays

NGS-Based Assays

More Assays

Customized Assays

Assays by Therapeutic Area

Solid Tumor - Pan-Solid Tumors - Lung Cancer - Stomach Cancer - Breast Cancer - Soft Tissue Sarcoma - Other Cancer Types

Blood Cancer

Solid Tumor

Blood Cancer
Clinical Testing
Quality Systems
Events
Contact Us

Home / CDx/IVD Products / PCR-Based Assays / AR-V7 Mutation Detection Kit

AR-V7 Mutation Detection Kit

Prostate cancer is one of the most common malignant tumors of the urinary system. Androgen receptor (AR) plays an important role in the occurrence and development of prostate cancer. It promotes the progression and metastasis of prostate cancer by regulating the expression of downstream genes. The mainstay of treatment for advanced prostate cancer is endocrine therapy, known as androgen deprivation therapy (ADT).

The FDA has approved abiraterone, a CYP17A1 inhibitor, and enzalutamide, a potent anti-androgen, as second-line treatments for metastatic prostate cancer, but during treatment, prostate cancer often develops drug resistance and progresses to castration Resistant prostate cancer (CRPC). AR-V7-negative patients treated with abiraterone and enzalutamide had significantly shorter clinical or radiographic progression-free survival and overall survival than AR-V7-positive patients. Studies have shown that AR-V7 is involved in the development of resistance to abiraterone and enzalutamide. The AR-V7 mutation detection kit independently developed by MEDx Translational Medicine based on dPCR platform is used for AR-V7 detection.

contact

Technical method

Digital PCR

Applicable platform

Xinyi TD-1 and ABI Quantstudio 3D

Recommended crowd

√Primary resistance to abiraterone/enzalutamide in newly diagnosed CRPC population

√Detect secondary drug resistance in CRPC patients taking abiraterone/enzalutamide

√ Predict the possible benefit of mHSPC patients from ADT combined with abiraterone/enzalutamide treatment

If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.

1. Customized or bulk orders of IVD/CDx products.

2. Get a quote for IVD/CDx products

3. Become our distributor

4. Get customized pharmaceutical service solutions

5.Learn more about our technology and R&D